Sarepta Therapeutics, Inc.: directors' dealings · United States · SEC (Form 4)

About Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. is a U.S.-listed biopharmaceutical company traded on the NASDAQ in the United States, with its headquarters in Cambridge, Massachusetts. For French-speaking investors in France, Belgium, and Switzerland, Sarepta stands out as a highly specialized precision-medicine company focused on rare diseases, especially neuromuscular disorders, and increasingly on a broader set of genetic-medicine and RNA-based programs. The company traces its corporate roots back to 1980, when it was originally incorporated in Oregon before reincorporating in Delaware in 2013. Historically, Sarepta built its reputation around phosphorodiamidate morpholino oligomer, or PMO, chemistry, which became an important platform in RNA-targeted therapeutics. Over time, the group established a strong competitive position in Duchenne muscular dystrophy (DMD), a rare-disease market characterized by high unmet medical need, intensive clinical scrutiny, and significant pricing power potential in exchange for specialized support and manufacturing capabilities. Sarepta’s lead asset is ELEVIDYS (delandistrogene moxeparvovec-rokl), an intravenous gene therapy that the company describes as the first and only approved gene therapy for Duchenne muscular dystrophy. In addition to ELEVIDYS, Sarepta markets a portfolio of PMO therapies for selected Duchenne patient subgroups, giving the company a commercial base that is broader than a single-asset story. Beyond Duchenne, Sarepta is advancing an expanding pipeline that includes siRNA and genetic-medicine programs targeting disorders such as myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), Huntington’s disease, idiopathic pulmonary fibrosis, and other muscle, central nervous system, and cardiac indications. From a competitive standpoint, Sarepta benefits from an early-mover and leadership position in Duchenne, but it also operates in a highly regulated environment where safety, durability of effect, manufacturing scale, and regulatory interpretation can materially affect valuation. Recent corporate news has highlighted both opportunity and risk. In 2025, the FDA requested suspension of certain Elevidys distribution and placed several gene-therapy trials on hold after reported deaths, underscoring the safety sensitivity of the platform. Subsequently, the FDA recommended lifting the voluntary hold for ambulatory patients, and Sarepta continued to communicate clinical updates. In 2026, the company reported positive three-year EMBARK data for ELEVIDYS and announced the commercial launch of ELEVIDYS in Japan through Chugai, indicating international expansion of the franchise. Geographically, Sarepta remains primarily U.S.-centered, with major operations in Cambridge and broader Massachusetts, including research, development, and manufacturing capabilities. The company also relies on international partnerships to extend reach outside the United States. In short, Sarepta is a specialized NASDAQ biotechnology name combining scientific leadership in Duchenne, an expanding rare-disease pipeline, and meaningful regulatory execution risk.